(Nasdaq: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for denosumab, a subcutaneous RANK Ligand inhibitor.
Amgen (Nasdaq: AMGN), today announced results of voting at the company's Annual Meeting of Stockholders, held at the Four Seasons Hotel Westlake Village in Westlake Village, Calif. Approximately 85 percent of outstanding shares were represented at the meeting.
Amgen today announced that four inspirational cancer survivors who have made a difference for others affected by cancer in their communities have been selected as Breakaway from Cancer(R) Champions to participate in Breakaway Miles during the 2010 Amgen Tour of California.
THOUSAND OAKS, Calif., April 29, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) will present at the Deutsche Bank 35th Annual Healthcare Conference on Tuesday, May 4, 2010 at the InterContinental, Boston, Mass., beginning at 9:20 a.m. Eastern Time. Senior Vice President of North America Commercial Operations Jim Daly will present.
Amgen (Nasdaq: AMGN) today announced that the Board of Directors has appointed Robert A. Bradway president and chief operating officer (COO), effective May 11.
--First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion --First Quarter 2010 GAAP Earnings Per Share Increased 20 Percent to $1.18 --Adjusting for Impact of U.S. Health Care Reform, 2010 Total Revenue and Adjusted EPS Expected Towards Lower End of Current Guidance Ranges of $15.1-$15.5 Billion and $5.05-$5.25, Respectively
Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Wednesday, April 21, 2010 after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time.
Amgen (Nasdaq: AMGN) today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL.
--Nine Genes Beyond KRAS Investigated As Potential Predictive Biomarkers For Metastatic Colorectal Cancer Therapy --ABSTRACT NUMBER: LBA 8791
